Eagle Bay Advisors’s NovoCure NVCR Stock Holding History

Eagle Bay Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7	Closed	-$1K	–	735
2021 Q4	$1K	Sell	7 -7	-50%	-$703	﹤0.01%	1033
2021 Q3	$2K	Buy	+14	New	+$2.12K	﹤0.01%	971

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eagle Bay Advisors's NVCR Position: Q1 2022 in Review

Eagle Bay Advisors sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 7 shares — an estimated $1K sold.

Eagle Bay Advisors first reported a position in NVCR in Q3 2021 and held it in 2 quarters. The position peaked at $2K in Q3 2021. 308 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

Eagle Bay Advisors reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
Eagle Bay Advisors sold 7 NovoCure shares in Q1 2022, an estimated $1K.
Eagle Bay Advisors first reported a position in NovoCure in Q3 2021 and held it in 2 quarters.
Eagle Bay Advisors's NovoCure position peaked at $2K in Q3 2021.
308 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Eagle Bay Advisors's 13F filing for Q1 2022, filed 11 May 2022.